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Trichomonas vaginalis is the etiological agent of trichomoniasis, the most common non-viral sexually
transmitted disease (STD) in world, with 276.4 million new cases each year. T. vaginalis can be naturally
infected with Mycoplasma hominis and Trichomonasvirus species. This study aimed to evaluate the preva-
lence of T. vaginalis infected with four distinct T. vaginalis viruses (TVVs) and M. hominis among isolates
from patients in Porto Alegre city, South Brazil. An additional goal of this study was to investigate
whether there is association between metronidazole resistance and the presence of M. hominis during
TVV infection. The RNA expression level of the pyruvate ferredoxin oxidoreductase (PFOR) gene was also
evaluated among metronidazole-resistant and metronidazole-sensitive T. vaginalis isolates. A total of 530
urine samples were evaluated, and 5.7% samples were positive for T. vaginalis infection. Among them,
4.51% were isolated from female patients and 1.12% were frommale patients. Remarkably, the prevalence
rates of M. hominis and TVV-positive T. vaginalis isolates were 56.7% and 90%, respectively. Most of the T.
vaginalis isolates were metronidazole-sensitive (86.7%), and only four isolates (13.3%) were resistant.
There is no statistically signiﬁcant association between infection by M. hominis and infection by TVVs.
Our results refute the hypothesis that the presence of the M. hominis and TVVs is enough to confer
metronidazole resistance to T. vaginalis isolates. Additionally, the role of PFOR RNA expression levels in
metronidazole resistance as the main mechanism of resistance to metronidazole could not be established.
This study is the ﬁrst report of the T. vaginalis infection by M. hominis and TVVs in a large collection of
isolates from South Brazil.
 2015 Elsevier B.V. All rights reserved.1. Introduction
Trichomoniasis is caused by the ﬂagellate protozoan
Trichomonas vaginalis and is the most common non-viral sexually
transmitted disease (STD), with an estimated incidence of 276.4
million new cases a year worldwide (WHO, 2012). This infection
has been associated with serious consequences, including adverse
pregnancy outcomes, infertility, predisposition to cervical cancer,
and pelvic inﬂammatory disease (Grodstein et al., 1993; Viikki
et al., 2000). Moreover, T. vaginalis is a cofactor in human immun-
odeﬁciency virus (HIV) transmission and acquisition, and tri-
chomoniasis was recently associated with aggressive prostate
cancers (Sutcliffe et al., 2006; Stark et al., 2009; Two et al., 2014).Metronidazole and tinidazole are nitroimidazoles that are the
two drugs of choice recommended by the Food and Drug
Administration (FDA, USA) for the treatment of human trichomoni-
asis (Helms et al., 2008). The prevalence of resistant isolates seems
to vary widely, achieving rates between 2.2% and 9.6% (Pérez et al.,
2001; Schwebke and Barrientes, 2006). Increasing reports of fail-
ures in the treatment of trichomoniasis and the rising prevalence
of metronidazole-resistant T. vaginalis isolates have occurred in
recent years, supporting the evidence that resistance is on the rise
(Klebanoff et al., 2001; Schwebke and Barrientes, 2006; Miller and
Nyirjesy, 2011; Kissinger, 2015). Though the mechanism of
metronidazole resistance in T. vaginalis from treatment failures is
not well understood, one hypothesis is that the resistance of T.
vaginalis to metronidazole occurs through several stages based
on the signiﬁcant reduction and eventual loss of activity of ferre-
doxin and pyruvate:ferredoxin oxidoreductase (PFOR), two
enzymes involved in drug activation. Consequently, the release
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group are inhibited, and microbicide radicals are not generated
(Rasoloson et al., 2002).
Some T. vaginalis clinical isolates can be naturally infected with
Mycoplasma hominis, a small intracellular bacterium frequently
found in the lower genital tract (Rappelli et al., 1998). The mecha-
nism of metronidazole resistance in T. vaginalis is not elucidated,
though some hypotheses speculate a potential role for coinfection
of TVVs andM. hominis in the increase of metronidazole resistance.
A strong relationship between M. hominis coinfection and metron-
idazole resistance in vitro was proposed (Xiao et al., 2006). In con-
trast, a lack of correlation in this association was described (Butler
et al., 2010).
In addition to M. hominis infection, T. vaginalis usually harbor
double-stranded RNA (dsRNA) viruses from the genus
Trichomonasvirus of the Totiviridae family (Weber et al., 2003;
Wendel et al., 2002). T. vaginalis viruses (TVVs) ﬁrst identiﬁed by
Wang and Wang (1985). TVVs form isometric viral particles that
contain a nonsegmented 4500–5000 bp dsRNA genome, and the
transmission of TVVs occurs upon cell division (Benchimol et al.,
2002; Goodman et al., 2011a). T. vaginalis can be infected with
up to four distinct TVVs (Goodman et al., 2011b). The precise con-
tribution of the virus in enhancing or decreasing the virulence of
this parasite is unknown, though some studies have contributed
to elucidate the role of TVVs during infection. These studies sug-
gest an association between the expression of immunogenic pro-
teins on the trichomonad surface, variations in protozoal
phenotypes, and upregulation of certain proteins which include
known virulence factors (Gerhold et al., 2009; Khoshnan and
Alderete, 1994).
Due to the paucity of clinical and molecular epidemiological
information, the association between T. vaginalis pathogenesis
and the presence of M. hominis and TVVs has not been deﬁnitively
established. The discrepancies noted in previous studies highlight
the need for epidemiological studies with a larger number of T.
vaginalis isolates that will contribute to an understanding of the
relationship between drug resistance and the genetic identity of
T. vaginalis isolates. Thus, we evaluated the prevalence of TVVs
andM. hominis infection in a large number of fresh T. vaginalis clin-
ical isolates from South Brazil. We also attempted to evaluate
whether an association exists between metronidazole resistance
and infection with TVVs and M. hominis. Moreover, we sought to
establish whether sensitive and resistant T. vaginalis isolates differ
in the RNA expression of the PFOR gene.2. Materials and methods
2.1. T. vaginalis isolates
A total of 30 fresh T. vaginalis isolates were isolated from urine
samples. The parasites were harvested consecutively at Laboratório
de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, UFRGS,
Brazil, and were registered and stored by cryopreservation at
80 C in the T. vaginalis isolates bank of our research team. Two
isolates, T. vaginalis 30236 and 30238, from the American Type
Culture Collection (ATCC) were also used. The virus-harboring iso-
late T. vaginalis 347 was used as a positive control in the TVV iden-
tiﬁcation assay. TheM. hominis-positive isolates were conﬁrmed by
16S rRNA sequencing.2.2. T. vaginalis isolation and in vitro culture
First, the urine samples were examined by direct microscopy
and subsequently inoculated onto trypticase-yeast
extract-maltose (TYM) medium (pH 6.0) supplemented withheat-inactivated bovine serum (HIBS 10% [v/v]) and incubated at
37 C (±0.5), as previously described (Diamond, 1957). The urine
samples were considered T. vaginalis negative after 5 days of cul-
ture. The positive samples were subcultured until axenization.
Thereafter, all experiments were performed using organisms in
the logarithmic phase of growth that exhibited motility and nor-
mal morphology, and all experiments were performed in triplicate
and with at least three independent assays.
2.3. Metronidaloze-susceptibility assay
Metronidazole susceptibility was assessed separately for each
isolate in this study after log growth was achieved. Brieﬂy, a stock
solution (9.35 mM) of metronidazole (Sigma) was prepared in
DMSO (4.0%) and TYM medium. Trichomonads were washed three
times with glucose (0.2%) saline solution and the concentration
was adjusted (5.0  104 trophozoites per well) and added to 12
serial dilutions (2,334–1.14 lM) of metronidazole in 96-well
plates. Plates were incubated at 37 C for 48 h under microaerophi-
lic conditions (5% CO2). After incubation, the plates were examined
using an inverted microscope to determine the MIC (minimum
inhibitory concentration), the lowest drug concentration at which
no motile trichomonads were observed at the end of the incuba-
tion period. Low-level resistance was deﬁned as an anaerobic
MIC 30–60 lM, moderate-level resistance as 60–120 lM, and
high-level resistance as 235 lM or greater as previously described
by Butler et al. (2010). The end point was conﬁrmed by the failure
of non-motile parasites to grow after re-inoculation into drug-free
medium (Rabiee et al., 2012). All experiments were carried out
thrice, in triplicate, and with a vehicle control (DMSO).
2.4. Detection of T. vaginalis isolates infected by M. hominis
2.4.1. Polymerase chain reaction (PCR) ampliﬁcation of 16S rRNA
M. hominis
The 16S rRNA M. hominis gene was detected by PCR ampliﬁca-
tion using primers previously described Blanchard et al. (1993):
forward 50 CAATGGCTAATGCCGGATACGC 30 and reverse
50GGTACCGTCAGTCTGCAAT 30. Total DNA was extracted from T.
vaginalis according to an adaptation of the method described in
previous study Butler et al. (2010). Brieﬂy, the DNA was extracted
from 4.0  106 trophozoites using a boiling based method: the tri-
chomonads were washed three times using glucose (0.2%) saline
solution and the pellet was resuspended in 200 lL of TE (10 mM
Tris 1.0 mM EDTA pH 8.0) buffer, boiled at 100 C for 20 min, and
centrifuged at 10.000g for 10 min. The supernatant containing
the DNA was stored at 20 C and subsequently used in PCR
assays.
Primers speciﬁc to the T. vaginalis 18S rRNA was used as an
internal reaction control: forward 50 TAATGGCAGAATCTTTGGAG
30, reverse 50 GAACTTTAACCGAAGGACTTC 30 (Blanchard et al.,
1993). Parallel reactions performed without DNA were included
as negative controls. Amplicons were analyzed on a 1.0% agarose
gel in Tris–Borate–EDTA (TBE) buffer containing ethidium bromide
(0.5 lg/mL) and photographed under UV visualization. The M.
hominis-speciﬁc and T. vaginalis-speciﬁc products were 334 and
312 bp, respectively. The negative results were conﬁrmed in three
independent experiments.
2.4.2. Identiﬁcation of 16S rRNA M. hominis by sequencing
The PCR product was puriﬁed using the PureLink Quick Gel
Extraction and PCR Puriﬁcation Combo Kit (Invitrogen™) for iden-
tiﬁcation of 16S rRNA M. hominis by sequencing. Samples were
sequenced by ACTGene Análises Moleculares Ltda. (Centro de
Biotecnologia, UFRGS, Porto Alegre, RS, Brazil) using an
ABI-PRISM 3100 Genetic Analyzer armed with 50 cm capillaries
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were labeled with 2.5 pmol of each primer (forward 50
CAATGGCTAATGCCGGATACGC 30 and reverse 50GGTACCGTCAGTC
TGCAAT 30) and 3 lL of BigDye Terminator v3.1 Cycle Sequencing
RR-100 (Applied Biosystems) in a ﬁnal volume of 10 lL. Labeling
reactions were performed using a GeneAmp PCR System 9700
(Applied Biosystems) thermocycler with an initial denaturing step
of 96 C for 3 min, followed by 25 cycles of 96 C for 10 s, 55 C for
5 s and 60 C for 4 min. Labeled samples were puriﬁed by iso-
propanol precipitation followed by rinsing with 70% ethanol.
Precipitated products were suspended in 10 lL formamide, dena-
tured at 95 C for 5 min, ice-cooled for 5 min and electroinjected
in the automatic sequencer. The similarity of nucleotides
sequences were evaluated using Basic Local Alignment Search
Tool (BLAST) and the 16S rRNA M. hominis sequence alignment
was made using ClustalW – Multiple Sequence Alignment (EBI,
United Kingdom).2.5. Detection of T. vaginalis harboring TVV and identiﬁcation of TVV
species
2.5.1. dsRNA extraction
All 33 isolates were screened and evaluated for the presence of
TVVs by dsRNA extraction. The dsRNA were extracted from
1.0  107 trophozoites using adaptations of protocols previously
described (Attoui et al., 2000; Goodman et al., 2011a).
Trichomonads were washed three times using glucose (0.2%) saline
solution (pH 8.0) and the total RNA was subsequently extracted
using TRIzol™ reagent (Invitrogen, Carlsbad, CA, USA) following
the manufacturer’s instructions. Next, contaminating
single-stranded RNA was selectively precipitated by incubation
with 4.0 M LiCl at 4 C overnight and centrifuged at 12.750g for
5 min. The dsRNA was precipitated by the addition of isopropanol
and ammonium acetate (7.5 M) and incubation at 20 C for 2 h.
Then, the samples were centrifuged at 12.750g for 5 min and
the pellets were resuspended in ethanol (75%) and centrifuged at
7.750g for 5 min. The pellets were dissolved in water to create
a working solution of dsRNA. Visualization of dsRNA was per-
formed with ethidium bromide (0.5 lg/mL) under UV transillumi-
nation after electrophoresis on 1.0% agarose gels. The presence of a
band between 4 kbp and 5 kbp was positive for Trichomonasvirus
(TVVs) (Goodman et al., 2011a).2.5.2. TVV species identiﬁcation by reverse transcriptase polymerase
chain reaction (RT-PCR)
All TVV-positive T. vaginalis isolates in the dsRNA initial screen-
ing were identiﬁed at the species level by an RT-PCR assay using
species-speciﬁc primers (Table 1) (Goodman et al., 2011a). All pri-
mers used ampliﬁed a 500 pb product. Brieﬂy, the dsRNA extracts
from cultured T. vaginalis organisms were used to carry out RT-PCR
using the Qiagen one-step RT-PCR kit (Qiagen) according to the
manufacturer’s instructions. Negative control was carried out with
no RNA template. The negative results were conﬁrmed in three
independent experiments.Table 1
TVVs species-speciﬁc primers for RT-PCR.
Primer name Sequence (50 – 30)
TVV1 forward ATTAGCGGTGTTTGTGATGCA
TVV1 reverse CTATCTTGCCATCCTGACTC
TVV2 forward GCTTGAGCACTGCTCGCG
TVV2 reverse TCTCTTTTGGCATCGCTT
TVV3 forward AAATTAATCAACACCCTCC
TVV3 reverse CAGATCACTTTGTGTGTC
TVV4 forward ATGCCAGTTGCTTTCCG
TVV4 reverse TTCCCCAATAGTTATCAG2.6. Relative RNA expressions levels of pyruvate-ferredoxin
oxidoreductase (PFOR)
To evaluate the possible role of PFOR in the metronidazole resis-
tance mechanism, the relative RNA expression levels of this gene
were evaluated in the metronidazole-sensitive T. vaginalis isolates
and those with low and moderate resistance levels. The tropho-
zoites were treated for 24 h with a low concentration of metron-
idazole (2 lM) before RNA extraction, and the trophozoites
cultivated without MTZ were used as the control. The PFOR primer
pair used, was designed for our previous study (unpublished data):
Forward 50CTCGTTTGGGGTGCTACATT30 and Reverse 50TCCTGATC
CCAAACCTTGAG30 (TVAG_198110; 239 bp). The total RNA was
extracted from 4.0  106 trophozoites/mL using TriZol™ follow-
ing the manufacturer’s instructions and stored 80 C until use.
Five 10-fold series dilutions starting from 100 ng of genomic
DNA was used to construct a standard curves in order to determine
PCR ampliﬁcation efﬁciencies, and all PCR efﬁciencies were greater
than 95%. Quantitative real-time PCR reactions (qRT-PCR) were
carried out in 0.1-mL microtubes using Qiagen’s real-time PCR sys-
tem, Rotor-Gene Q and the Rotor-Gene™ SYBR™ Green RT-PCR kit
(Qiagen™). Each PCR reaction contained 6 lL of 2 of Rotor-Gene
SYBR Green PCR Master Mix, 200 nM of each primer, 0.125 lL of
Rotor-Gene RT Mix and 100 ng of RNA template in a total volume
of 12 lL. The cycling conditions were as follows: an initial step at
55 C for 10 min for reverse transcription; an enzyme activation
step at 95 C for 10 min; 35 cycles of denaturation at 95 C for
15 s; and annealing and extension at 64 C for 30 s, with ﬂuores-
cence data collection in this step. Melting curve analyses were per-
formed by raising the temperature at the end of each run in by 1 C
per 5 s from 63 C or 64 C to 95 C. Parallels reactions without RNA
or DNA templates were run as negative controls. Three biological
replicate samples were analyzed in three technical replicates under
each experimental condition.
The relative change in gene expression was analyzed using the
2DDCt method (Livak and Schmittgen, 2001). The levels of PFOR
mRNA were quantiﬁed by qRT-PCR analysis relative to a-tubulin
and actin mRNA as reference genes, as previously determined by
us (unpublished data). Three technical replicates from three bio-
logical replicates were analyzed.
2.7. Statistical analysis
The existence of an association between the MIC value for
metronidazole and the presence or absence of M. hominis and
TVVs was analyzed using a X2 test following residual analysis. All
statistical analyses were performed in SPSS 18.0 (SPSS Inc.,
Chicago, IL, USA), and a p value <0.05 was considered statistically
signiﬁcant. The statistical signiﬁcance of the RNA expression
changes of PFOR between sensitive and resistant T. vaginalis iso-
lates were calculated using one-way ANOVA. The level of signiﬁ-
cance was also determined by the Bonferroni method comparing
all groups versus the control (P < 0.05).
2.8. Ethical aspects
This study was submitted and approved by the UFRGS Ethical
Committee, number 18923.3. Results
3.1. T. vaginalis isolation
Five hundred and thirty urine samples were collected in a sur-
vey spanning a two-year period (2011–2012). Overall, 30 out of
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One long-term grown T. vaginalis isolate cultivated at the labora-
tory (347 isolate, from the USA) and two ATCC isolates (30236
and 30238) were included in this study for a total enrollment of
thirty-three T. vaginalis isolates. Considering only the fresh T. vagi-
nalis isolates, a total of 4.5% (24 out of 530) were isolated from
female patients and 1.1% (6 out of 530) were isolated from male
patients. The minimum and maximum of age among women with
trichomoniasis was 15 and 74 years and the mean of age was
49.9 ± 21.4 SD years. The highest infection rate occurred among
younger women: 41.7% were less than 25 years old. In addition, a
high rate of infection was observed among older women (>60 years
old), accounting for 33% of the T. vaginalis-infected women. The
mean age of T. vaginalis-infected men was 69.8 ± 19.9 SD years,
which ranged from 41 to 87 years.3.2. T. vaginalis isolates were infected by M. hominis
The presence ofM. hominis was detected in 56.7% (17 out of 30)
fresh clinical T. vaginalis isolates (Table 2). Taking into considera-
tion only the fresh T. vaginalis isolates, the prevalence ofM. hominis
infection was 62.5% (15 out of 24) among female patients, whereas
among male patients, the prevalence was lower at 33.3% (2 out of
6). The long-term grown cultivated isolate (347) and the ATCC iso-
lates (30236 and 30238) were also M. hominis-infected. The PCR
ampliﬁcation for each T. vaginalis isolate was assessed by agarose
gel electrophoresis and the M. hominis infection was conﬁrmed
by the presence of a 320 pb ampliﬁcation product (data not
shown). All 20 positive isolates for 16S RNA M. hominis in the
PCR reactions were also correctly identiﬁed as M. hominis by 16STable 2
MIC values for metronidazole and Trichomonas vaginalis isolates infected by
Mycoplasma hominis and TVV species.
Long-term grown
isolates
MIC
(lM)
M.
hominis
TVV1 TVV2 TVV3 TVV4
ATCC236 1.14 + +  + 
ATCC238 9.12 +   + 
347 4.56 + +   
Fresh clinical isolates
TV-LACM1 9.12  +   
TV-LACM2 18.25 +   + 
TV-LACM3 9.13  +   
TV-LACM4 9.13  +   
TV-LACM5 4.56 + +   
TV-LACM6 18.25 + +   
TV-LACM7 18.25 + +   
TV-LACM8 9.13 + + +  
TV-LACM9 4.56 + +   
TV-LACM10 9.13  +   
TV-LACM11 9.13 +  + + +
TV-LACM12 18.25 + +  + 
TV-LACM13 4.56 + + +  
TV-LACM14 36.50 +    
TV-LACM15 73.00     
TV-LACM16 4.56 +  + + 
TV-LACM17 18.25 + + + + 
TV-LACM18 4.56  +   
TV-LACM19 36.50   +  
TV-LACM20 9.13 + +   +
TV-LACM21 4.56   +  
TV-LACM22 18.25 +    
TV-LACM23 36.50    + 
TV-LACM24 18.25 + + + + 
TV-LACH1 4.56 + +   
TV-LACH2 18.25  +   
TV-LACH3 9.13  +   
TV-LACH4 9.13  + + + +
TV-LACH5 9.13  +   
TV-LACH6 9.13 + +  + RNA gene sequencing. The similarities values ranged from 98% to
100%. The alignment of fourM. hominis-positive T. vaginalis isolates
is shown in Fig. 1 and Supplemental Figure 1.
3.3. High rates of T. vaginalis isolates harboring TVV species
We found a high number of TVV-positive T. vaginalis isolates by
dsRNA initial screening and by RT-PCR assay for identiﬁcation at
the species level; all given a speciﬁc 500 pb ampliﬁcation product
(data not shown). Regarding the presence of TVVs, 90% (27 out of
30) of the T. vaginalis isolates harbored viruses (Table 2). Among
these, 33.3% (10 out of 30) were infected with more than one
TVV species. TVV1 was the most prevalent species (77.5%),
followed by TVV2 and TVV3 (30%). The least frequent species
was TVV4 (10%) (Table 2). The prevalence of TVV infection among
T. vaginalis isolated from female patients was 87.2% (21 out of 24)
while among isolates from male patients, the prevalence of
TVV-infection was 100% (6 of 6).
3.4. T. vaginalis isolates metronidazole susceptibility
The results of the in vitro metronidazole susceptibility experi-
ments are described in Table 2. Most of the isolates 86.7% (26 of
30) evaluated in this study were metronidazole sensitive, with
MIC values ranging from between 1.14 lM to 18.25 lM. Of the
30 T. vaginalis fresh isolates, four (13.3%) were metronidazole resis-
tant. The TV-LACM14, TV-LACM19 and TV-LACM23 isolates pre-
sented MIC values of 36.5 lM and therefore had low-level
resistance. The TV-LACM15 isolate had moderate-level resistance
with a MIC value of 73 lM. The statistical analysis showed no asso-
ciation between both TVV and M. hominis infection (P = 0.245 and
0.24, respectively) and metronidazole resistance in T. vaginalis.
3.5. PFOR RNA expression is not the main mechanism of resistance to
metronidazole
The relative RNA expression levels of PFOR from four T. vaginalis
isolates with different metronidazole resistance proﬁles are
described in Fig. 2. The mRNA levels of PFOR were lowest in both
isolates of TV-LACM15, which had moderate-level metronidazole
resistance, and in TV-LACM14, which had low-level metronidazole
resistance. The expression level of PFOR mRNA was highest in
TV-LACM19, which had low-level metronidazole resistance, and
in ATCC 30238, which is metronidazole-sensitive.4. Discussion
Metronidazole and tinidazole are nitroimidazoles and are the
drugs of choice recommended by the Food and Drug
Administration (FDA, USA) for the treatment of human trichomoni-
asis (Helms et al., 2008). The prevalence of resistant isolates seems
to vary widely, ranging from 2.2% to 9.6% (Pérez et al., 2001;
Schwebke and Barrientes, 2006). Increasing reports of failures in
the treatment of T. vaginalis infection and metronidazole-
resistant T. vaginalis isolates have occurred over recent years, and
evidence suggests that resistance may be increasing (Miller and
Nyirjesy, 2011). In our ﬁndings, 13.3% of the fresh T. vaginalis
isolates were metronidazole resistant, although none of them
had high levels of resistance. The TV-LACM14, TV-LACM19 and
isolates had low resistance whereas the TV-LACM15 isolate was
moderately resistant. These results are similar to results obtained
in a previous surveillance study in the US, which found that 4.3%
of 538 T. vaginalis isolates exhibited low-level in vitro metronida-
zole resistance. However, in that same study, T. vaginalis with
moderate or high-level resistance were not found (Kirkcaldy
CLUSTAL 2.1 Multiple Sequence Alignment
ATCC30238       TTCATCGTGCACGCTGTGTCGCTCCATCAAGCTTTCGCTCATTGTGGAATATTCCCTACT
TVLACM14        TTCATCGTGCACGCTGTGTCGCTCCATCAAGCTTTCGCTCATTGTGGAATATTCCCTACT
TVLACM11        TTCATCGTGCACGCTGTGTCGCTCCATCAAGCTTTCGCTCATTGTGGAATATTCCCTACT
TVLACH6 TTCATCGTGCACGCTGTGTCGCTCGATCAAGCTTTCGCTCATTGTGGAATATTCCCTACT
************************ ***********************************
ATCC30238       GCTGCCTCCCGTAGGAGTTTGGGCCGTATCTCAGTCCCAATGTGGCCGTTCAGTCTCTCG
TVLACM14        GCTGCCTCCCGTAGGAGTTTGGGCCGTATCTCAGTCCCAATGTGGCCGTTCAGTCTCTCG
TVLACM11        GCTGCCTCCCGTAGGAGTTTGGGCCGTATCTCAGTCCCAATGTGGCCGTTCAGTCTCTCG
TVLACH6 GCTGCCTCCCGTAGGAGTTTGGGCCGTATCTCAGTCCCAATGTGGCCGTTCAGTCTCTCG
************************************************************
ATCC30238       ACCCGGCTAAACATCATAGTCTTGGTGGGCCATTACCTCACCAACTAACTAATGTTCCGC
TVLACM14        ACCCGGCTAAACATCATAGTCTTGGTGGGCCATTACCTCACCAACTAACTAATGTTCCGC
TVLACM11    ACCCGGCTAAACATCATAGTCTTGGTGGGCCATTACCTCACCAACTAACTAATGTTCCGC
TVLACH6 ACCCGGCTAAACATCATAGTCTTGGTGGGCCATTACCTCACCAACTAACTAATGTTCCGC
************************************************************
ATCC30238       ACCCTCATCTTTTAGTGGCGCCTTACAGCGCCTTTCACAACGGAACCATGCGGTTCCATG
TVLACM14        ACCCTCATCTTTTAGTGGCGCCTTACAGCGCCTTTCACAACGGAACCATGCGGTTCCATG
TVLACM11        ACCCTCATCTTTTAGTGGCGCCTTACAGCGCCTTTCACAACGGAACCATGCGGTTCCATG
TVLACH6 ACCCTCATCTTTTAGTGGCGCCTTACAGCGCCTTTCACAACGGAACCATGCGGTTCCATG
************************************************************
ATCC30238       CGTATCCGGCATTAGCCATTGA
TVLACM14        CGTATCCGGCATTAGCCATTGA
TVLACM11        CGTATCCGGCATTAGCCATTGA
TVLACH6 CGTATCCGGCATTAGCCATTGA
**********************
Fig. 1. Multiple 16s RNAMycoplasma hominis sequence alignment obtained by ClustalW. The sequences are representative of control, ATCC 30238 (metronidazole-sensitive),
and fresh clinical isolates: TV-LACM14, low-level resistance and no TVV infection; TV-LACM11, metronidazole-sensitive, harboring TVV2, TVV3 and TVV4; TV-LACH6,
metronidazole-sensitive, harboring TVV1 and TVV3.
Fig. 2. Relative PFOR RNA expression of four T. vaginalis isolates with different
metronidazole sensitivity proﬁles. TV-LACM15, moderate metronidazole resis-
tance; TV-LACM14 and TV-LACM19, low metronidazole resistance; ATCC30236
metronidazole sensitive. The bars and errors bars represent the value and standard
deviation from the relative RNA expression of PFOR obtained from three indepen-
dent experiments performed in triplicate. (⁄) indicates a signiﬁcant difference.
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and Barrientes, 2006) found 17.6% of T. vaginalis isolates had mod-
erate to high metronidazole resistance levels. Considering these
results from different regions of the world may highlight the
possibility that reliance on a single class of antimicrobial drugs
for treating T. vaginalis infections may heighten the vulnerability
to the emergence of resistance. Consequently, novel treatment
options are needed.
Trichomoniasis is characterized by signiﬁcant heterogeneity in
its clinical presentation, metronidazole sensitivity and its contribu-
tion to increasing the host susceptibility to other infectious agents.
However, it is not clear whether this clinical variability is more
inﬂuenced by host factors or by differences in the phenotypic
expression of individual T. vaginalis isolates (Meade et al., 2009).
Therefore, after considering age and sex in characterizing patients
with trichomoniasis proﬁles, our concern was the molecularepidemiology among T. vaginalis isolates. In support of our ques-
tion and to our best knowledge, there is no molecular epidemiol-
ogy data from T. vaginalis isolates from any region of Brazil. We
also attempted to understand whether there is any association
between metronidazole resistance and molecular aspects, such as
the presence ofM. hominis and TVV, in fresh clinical T. vaginalis iso-
lates. Thirty-three isolates from female and male patients, includ-
ing both fresh and ATCC organisms, were tested for their
susceptibility to metronidazole and the presence of M. hominis
and TVVs.
The ability of M. hominis to invade, survive and multiply in the
cytoplasm of T. vaginalis is an important defense mechanism of
these bacteria during human infection because the parasite plays
a ‘‘Trojan horse’’ role (Dessì et al., 2005, 2006) by providing a pro-
tected niche for the survival of the bacterium. Our study is the ﬁrst
report employing sequencing methodology to certify this analysis
and we found that 56.7% of fresh T. vaginalis isolates were infected
withM. hominis. This result corroborates with the study performed
in 28 T. vaginalis isolates from China, which found that 50% of the
parasites were infected by this bacterium (Xiao et al., 2006).
However, the prevalence described in the literature varies widely.
A study was conducted with 40 isolates from different geographi-
cal regions (Italy, Angola, and Mozambique), and 37 (92.5%) were
infected with M. hominis (Rappelli et al., 2001). In contrast, other
studies found a lower prevalence of infected isolates (20% and
25%, respectively) (Butler et al., 2010; Hampl et al., 2001). The
presence of M. hominis in association with T. vaginalis has impor-
tant clinical implications and this symbiosis has been correlated
with the metronidazole resistance of the parasite (Xiao et al.,
2006). However, the present study revealed a high incidence of T.
vaginalis isolates infected by M. hominis, most of which were sus-
ceptible to metronidazole. These important ﬁndings conﬁrm the
results that showed no association between metronidazole resis-
tance and M. hominis infection (Butler et al., 2010) and do not sup-
port the hypothesis that the presence of M. hominis is sufﬁcient to
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2006).
Approximately one half of all T. vaginalis isolates are infected
with dsRNA or VLP viruses (Gerhold et al., 2009). However, a large
variability is observed in the prevalence of this infection. Our study
found that 90% of the fresh isolates were infected with TVVs, con-
ﬁrming the high prevalence observed in previously study that
found dsRNA particles in 82% of T. vaginalis isolates in South
Africa (Weber et al., 2003). A study conducted in Korea found that
only 13.6% of the isolates were infected with TVVs, showing that
the infection rate may vary according to geographical location
(Kim et al., 2007). Regarding the prevalence of TVVs species,
TVV1 was found to be the most prevalent, followed by TVV2,
TVV3, and TVV4. Five T. vaginalis isolates were investigated and
also found that TVV1 was the most prevalent species Goodman
et al. (2011a). In contrast, other researchers (Fraga et al., 2012)
considered only TVV1 and TVV2 species and found a higher preva-
lence of TVV2 (Xiao et al., 2006) relative to TVV1 (Helms et al.,
2008) among 21 T. vaginalis isolates. Three of their isolates were
co-infected with both species (14.3%). As 10 of 30 (33.3%) infected
isolates showed more than one TVV species, the prevalence of
co-infection was higher in our study.
The association between the presence of TVVs and metronida-
zole resistance in T. vaginalis has been suggested elsewhere
(Snipes et al., 2000; Hampl et al., 2001). However, our ﬁndings
clearly demonstrate the lack of relationship between the presence
of TVVs and metronidazole resistance because 90% of the isolates
were infected with TVVs and most of them were metronidazole-
sensitive. Furthermore and importantly, TV-LACM15 was the only
moderately metronidazole-resistant isolate, but was TVVs- and
M. hominis-free. Though the mechanism of metronidazole resis-
tance in T. vaginalis is not fully understood, the most accepted
hypothesis is that resistance is achieved through a decrease or loss
of ferredoxin (Fdx) and pyruvate ferredoxin oxidoreductase (PFOR)
enzymatic activity involved in drug activation (Rasoloson et al.,
2002). Moreover, metronidazole resistance involves the loss of
multiple hydrogenosomal proteins, including Fdx, PFOR, malic
enzyme (ME), and hydrogenase (Land et al., 2004). Our ﬁndings
do not support the role of PFOR RNA expression as the main mech-
anism of resistance to metronidazole. Although PFOR RNA expres-
sion was down-regulated in TV-LACM15 and TV-LACM14 isolates,
which had moderate and low resistance levels, respectively, the
PFOR RNA expression level in the TV-LACM19 isolate with low level
resistance was higher than in ATCC30238, which is a
metronidazole-sensitive isolate.
The complete T. vaginalis genome sequence published by
Carlton et al. (2007) is a good starting point and greatly facilitates
basic research in molecular biology, particularly for metronidazole
resistance. Thus, it could easily lead to the identiﬁcation of genetic
markers for resistance and development of molecular tests,
although the genome available is frommetronidazole sensitive iso-
late. Nowadays, the complete understanding of metronidazole
resistance has been challenged because of the size, complexity,
and repetitiveness of the T. vaginalis genome. For example, other
possible mechanisms were identiﬁed, along with the presence of
nitroreductase NimA-like genes, which have been implicated in
metronidazole resistance in bacteria. In addition, a recent study
identiﬁed single nucleotide polymorphisms (SNPs) in two nitrore-
ductase genes (ntr4Tv and ntr6Tv) associated with resistance
(Paulish-Miller et al., 2014). Consequently, further molecular stud-
ies are necessary to establish the exact mechanism of drug resis-
tance in T. vaginalis.
Overall, our ﬁndings demonstrated a high prevalence of T. vagi-
nalis isolates infected with bothM. hominis and different TVVs spe-
cies. Moreover, a major metronidazole-sensitivity proﬁle was also
observed. Thus, our data strongly suggest that a symbioticrelationship between these bacteria, the viruses and the protozoa
is not associated with drug resistance. Our current efforts are
aimed at addressing whether the presence of M. hominis and
TVVs may modulate the pathogenesis of T. vaginalis isolated from
Brazil.
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